Get to know our clinical trials
Unmasked assay of RAY21 to inhibit the classical complement pathway in immunological diseases
THE MAIN OBJECTIVE IS TO EVALUATE THE SAFETY AND TOLERABILITY OF MULTIPLE S.C. ADMINISTRATIONS OF RAY121 IN PATIENTS WITH COMPLEMENT IMMUNODEFICIENCIES
Specialist
Hematology and Hemotherapy Department
Madrid headquarters
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE IB UNMASKED BASKET TRIAL OF RAY21 TO INHIBIT THE CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES
- Code EudraCT: 2023-507692-21-00
- Protocol number: RAY902CT
- Promoter: Chugai Pharmaceutical
- Molecule/Drug: RAY121
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.